Literature DB >> 29669277

Modulation of Tau Isoforms Imbalance Precludes Tau Pathology and Cognitive Decline in a Mouse Model of Tauopathy.

Sonia Lorena Espíndola1, Ana Damianich1, Rodrigo Javier Alvarez2, Manuela Sartor1, Juan Emilio Belforte2, Juan Esteban Ferrario3, Jean-Marc Gallo4, María Elena Avale5.   

Abstract

The microtubule-associated protein tau regulates myriad neuronal functions, such as microtubule dynamics, axonal transport and neurite outgrowth. Tauopathies are neurodegenerative disorders characterized by the abnormal metabolism of tau, which accumulates as insoluble neuronal deposits. The adult human brain contains equal amounts of tau isoforms with three (3R) or four (4R) repeats of microtubule-binding domains, derived from the alternative splicing of exon 10 (E10) in the tau transcript. Several tauopathies are associated with imbalances of tau isoforms, due to splicing deficits. Here, we used a trans-splicing strategy to shift the inclusion of E10 in a mouse model of tauopathy that produces abnormal excess of 3R tau. Modulating the 3R/4R ratio in the prefrontal cortex led to a significant reduction of pathological tau accumulation concomitant with improvement of neuronal firing and reduction of cognitive impairments. Our results suggest promising potential for the use of RNA reprogramming in human neurodegenerative diseases.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MAPT; alternative splicing; dementia; gene therapy; neurodegeneration; tauopathy

Mesh:

Substances:

Year:  2018        PMID: 29669277     DOI: 10.1016/j.celrep.2018.03.079

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  17 in total

Review 1.  Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease.

Authors:  Jangampalli Adi Pradeepkiran; Arubala P Reddy; P Hemachandra Reddy
Journal:  Drug Discov Today       Date:  2018-11-16       Impact factor: 7.851

2.  Distinct Neurotoxic Effects of Extracellular Tau Species in Primary Neuronal-Glial Cultures.

Authors:  Katryna Pampuscenko; Ramune Morkuniene; Lukas Krasauskas; Vytautas Smirnovas; Taisuke Tomita; Vilmante Borutaite
Journal:  Mol Neurobiol       Date:  2020-10-01       Impact factor: 5.590

Review 3.  Alzheimer's disease: phenotypic approaches using disease models and the targeting of tau protein.

Authors:  Elisabetta Lauretti; Domenico Praticò
Journal:  Expert Opin Ther Targets       Date:  2020-03-06       Impact factor: 6.902

Review 4.  Alternative splicing in Alzheimer's disease.

Authors:  Angela Amato; Elisa Belloni; Anna Di Matteo; Lucia Infantino; Davide Pradella; Giuseppe Biamonti; Claudia Ghigna
Journal:  Aging Clin Exp Res       Date:  2019-10-03       Impact factor: 3.636

5.  Interneuron NMDA Receptor Ablation Induces Hippocampus-Prefrontal Cortex Functional Hypoconnectivity after Adolescence in a Mouse Model of Schizophrenia.

Authors:  Rodrigo J Alvarez; Diego E Pafundo; Camila L Zold; Juan E Belforte
Journal:  J Neurosci       Date:  2020-03-23       Impact factor: 6.167

6.  Alzheimer-like amyloid and tau alterations associated with cognitive deficit in temporal lobe epilepsy.

Authors:  Sarah Gourmaud; Haochang Shou; David J Irwin; Kimberly Sansalone; Leah M Jacobs; Timothy H Lucas; Eric D Marsh; Kathryn A Davis; Frances E Jensen; Delia M Talos
Journal:  Brain       Date:  2020-01-01       Impact factor: 13.501

7.  Tau Phosphorylation and Aggregation in the Developing Human Brain.

Authors:  Marco M Hefti; SoongHo Kim; Aaron J Bell; Ryan K Betters; Kimberly L Fiock; Megan A Iida; Martin E Smalley; Kurt Farrell; Mary E Fowkes; John F Crary
Journal:  J Neuropathol Exp Neurol       Date:  2019-10-01       Impact factor: 3.685

8.  Tau exhibits unique seeding properties in globular glial tauopathy.

Authors:  Dah-Eun Chloe Chung; Yari Carlomagno; Casey N Cook; Karen Jansen-West; Lillian Daughrity; Laura J Lewis-Tuffin; Monica Castanedes-Casey; Michael DeTure; Dennis W Dickson; Leonard Petrucelli
Journal:  Acta Neuropathol Commun       Date:  2019-03-07       Impact factor: 7.801

9.  Marked Mild Cognitive Deficits in Humanized Mouse Model of Alzheimer's-Type Tau Pathology.

Authors:  Joshua D Cho; Yoon A Kim; Elizabeth E Rafikian; Mu Yang; Ismael Santa-Maria
Journal:  Front Behav Neurosci       Date:  2021-05-21       Impact factor: 3.558

10.  Fyn knockdown prevents levodopa-induced dyskinesia in a mouse model of Parkinson's disease.

Authors:  Melina P Bordone; Ana Damianich; M Alejandra Bernardi; Tomas Eidelman; Sara Sanz-Blasco; Oscar S Gershanik; M Elena Avale; Juan E Ferrario
Journal:  eNeuro       Date:  2021-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.